2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.431

Change

-0.10 (-1.53)%

Market Cap

USD 0.52B

Volume

0.44M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.13 (+0.25%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.28%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.01 (-0.04%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.04 (+0.12%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.01 (+0.04%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.29%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+0.30 (+0.21%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.14 (+0.27%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.10 (-0.10%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.58 (-0.26%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.61% 59% D- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.61% 57% F 59% D-
Trailing 12 Months  
Capital Gain 28.75% 77% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.75% 77% C+ 76% C+
Trailing 5 Years  
Capital Gain 42.88% 69% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.88% 66% D+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.16% 48% F 49% F
Dividend Return 5.16% 47% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.24% 46% F 56% F
Risk Adjusted Return 38.98% 41% F 45% F
Market Capitalization 0.52B 66% D+ 58% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.